RANDOMIZED NON-INFERIORITY TRIAL COMPARING OVERALL SURVIVAL OF PATIENTS MONITORED WITH SERUM TUMOR MARKER DIRECTED DISEASE MONITORING (STMDDM) VERSUS USUAL CARE IN PATIENTS WITH METASTATIC HORMONE RECEPTOR POSITIVE BREAST CANCER

Contact:

NCT Number:

Protocol:

AAAR9954

Study Status:

Active/Enrolling

Population:

Adult

Phase:

NA

The purpose of this study is to determine if overall survival of patients monitored with serum tumor marker direct disease monitoring (STMDDM) is as good as the overall survival of patients monitored with the usual care.

Are you Eligible? (Inclusion Criteria)

  • Do you have hormone positive, HER-2 negative, metastatic breast cancer?
  • Are you 18 years of age or older?
  • Are you willing to be monitored for your disease for the duration of this study?

Specialty Area(s)

Principal Investigator

Profile Headshot
  • Director, Hematology and Medical Oncology Fellowship Program
  • Director, Quality and Patient Safety, Division of Hematology and Oncology

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032